Dishman Carbogen: USFDA concludes inspection of Bavla unit

The company informed that USFDA has completed the inspection of its Bavla facility on October 26, 2018. The inspection was concluded successfully without any major or critical observations.

Dishman Carbogen Amcis is engaged in providing innovative solutions for the development and supply of drug substances and drug products, globally. The company provides fully-integrated CRAMS services to global pharma companies. The company manufactures and supplies marketable molecules including bulk drugs, intermediates, speciality chemicals, vitamins and disinfectants.

With this US Food and Drug Administration (USFDA) inspection, the company's facilities in Bavla and Naroda in India and multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.

Reacting to this development, at 12.10 am on Monday, the stock of Dishman Carbogen was trading at a price of Rs. 231.15 per share, up by 1.78 per cent on BSE exchange. While the benchmark index BSE Sensex traded at 33,651, higher by 301 points higher.